METHOD FOR PREDICTING THE RISK OF POOR TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH INVASIVE BREAST CANCER Russian patent published in 2019 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention is a method for predicting the risk of a poor tumor response to neoadjuvant chemotherapy (NAC) in patients with invasive breast carcinoma, characterized in that the value of the parameter Y in the regression equation is calculated using the formula Y=-4.88+10*X1-32.36*X2+6.81*X3+38.28*X4, where X1 is the degree of malignancy: X1=1 with low, X1=2 with moderate, X1=3 with high degree of malignancy; X2 – the state of the patient's menstrual function: X2 = 1 with maintaining menstrual function, X2 = 2 with menopause; X3 – the threshold value of circulating tumor cells (CTC) without signs of epithelial-mesenchymal transition (EMT) before the start of treatment: X3=0 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin- less than 0.19 cells/mcl, X3=1 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin- more than or equal to 0.19 cells/mcl; X4 – is the threshold value of the CTC with a sign of EMT before the start of treatment: X4=0 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin+ less than 0.24 cells/mcl, X4=1 with the content of cells with phenotype EpCam+CD45-CD44-CD24-Ncadherin+ more than or equal to 0.24 cells/mcl; further, the value of the probability of the risk of a poor response to neoadjuvant chemotherapy P is determined by the formula P=e^Y/(1+e^Y), where e – is a mathematical constant equal to 2.72, and with probability P≥0.5, high risk is determined, and if the probability is P<0.5, there is low risk of a poor response to neoadjuvant chemotherapy.

EFFECT: invention provides improved accuracy and informativeness of prediction.

1 cl, 2 ex, 3 tbl